Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.44 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 5/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.38 |
| ▸ | GJB2 | P29033 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28916072 | 0.88 | SSTR1 (0.56) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL3155877 | 0.86 | SSTR1 (0.53) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL24996978 | 0.83 | SSTR5 (0.47) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL14490124 | 0.83 | PTPN1 (0.44) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL3155871 | 0.83 | SSTR5 (0.47) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL22677468 | 0.83 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL22721951 | 0.78 | SSTR1 (0.41) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6667240 | 0.78 | SSTR1 (0.56) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL18671706 | 0.78 | SSTR1 (0.56) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6890255 | 0.78 | SSTR1 (0.48) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833361-B2 | Compound for use in the treatment of viral diseases | RIBAPHARM, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20030028013-A1 | Novel nucleosides having bicyclic sugar moiety | CEQUENT PHARMACEUTICALS, INC. | 2003-02-06 | — | — | US | disclosed |
| US-6403566-B1 | CONFORMATIONALLY LOCKED; ANTIVIRAL, ANTICANCER, STABILITY TO CELLULAR NUCLEASES AND STRONG BINDING AFFINITY TO NUCLEIC ACID TARGETS. | ICN PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1082012-A4 | NOVEL NUCLEOSIDES HAVING BICYCLIC SUGAR MOIETY | ICN PHARMACEUTICALS (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1082012-A1 | NOVEL NUCLEOSIDES HAVING BICYCLIC SUGAR MOIETY | ICN Pharmaceuticals, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999060855-A1 | NOVEL NUCLEOSIDES HAVING BICYCLIC SUGAR MOIETY | ICN PHARMACEUTICALS, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028013-A1 | Novel nucleosides having bicyclic sugar moiety | DCK, NUDT14, UCK2 | SSTR1 3893/4885SSTR2 3595/4885SSTR4 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.